Edap Tms (EDAP) Stock Price, News & Analysis

Company Overview

EDAP TMS (NASDAQ:EDAP) is a global medical device company specializing in non-invasive therapeutic ultrasound technologies. The company develops, manufactures and markets systems designed to treat prostate cancer and urological conditions through high-intensity focused ultrasound (HIFU) and extracorporeal shock wave lithotripsy. EDAP’s solutions are intended to provide precise, targeted therapy with reduced recovery times and minimal side effects compared to traditional surgical approaches.

EDAP’s oncology portfolio centers on its Focal One® and Ablatherm® HIFU platforms, which use real-time imaging guidance to ablate prostate tissue. Focal One is engineered for focal therapy, potentially limiting treatment to cancerous regions and preserving healthy tissue, while Ablatherm offers whole-gland ablation. In urology, the company’s Litho® series employs lithotripsy to fragment kidney stones using acoustic shock waves, with models such as Sonolith® i-moved designed for mobile and hospital settings. EDAP continually invests in R&D to enhance workflow, imaging precision and patient comfort across its product lines.

Founded in Lyon, France, in 1979, EDAP TMS has grown from its initial focus on extracorporeal lithotripsy into a multi-segment medical technology enterprise. The company established its U.S. subsidiary in the early 1990s and has since achieved regulatory clearances from bodies including the U.S. Food and Drug Administration and the European CE mark. EDAP’s commercial network spans North America, Europe, Latin America and Asia, partnering with leading hospitals, cancer centers and specialist practitioners to broaden access to its minimally invasive treatments.

Under the leadership of Chief Executive Officer Stephan H. Conrad, EDAP TMS emphasizes clinical collaboration and evidence-based practice to drive adoption of its technologies. The management team comprises industry veterans in medical device development, regulatory affairs and global sales. Through strategic alliances and ongoing clinical trials, EDAP aims to expand indications for its therapeutic ultrasound platforms while maintaining a focus on patient outcomes, operational efficiency and sustainable growth in emerging and established markets alike.

Key Stats

• Today's Range: $1.50 to $1.59
• 50-Day Range: $1.53 to $2.30
• 52-Week Range: $1.26 to $5.27
• Volume: 42,240 shs
• Average Volume: 98,851 shs
• Market Capitalization: $57.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.50
• Consensus Rating: Hold

Edap Tms Stock Analysis - MarketRank™

Edap Tms scored higher than 62% of companies evaluated by MarketBeat, and ranked 582nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Edap Tms has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Edap Tms has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Edap Tms are expected to grow in the coming year, from ($0.60) to ($0.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edap Tms is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edap Tms is -2.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Edap Tms has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.16% of the float of Edap Tms has been sold short.

Short Interest Ratio / Days to Cover

Edap Tms has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edap Tms has recently decreased by 5.31%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edap Tms does not currently pay a dividend.

Dividend Growth

Edap Tms does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.16% of the float of Edap Tms has been sold short.

Short Interest Ratio / Days to Cover

Edap Tms has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edap Tms has recently decreased by 5.31%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Edap Tms has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Edap Tms this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Edap Tms to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Edap Tms insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.23% of the stock of Edap Tms is held by insiders.

Percentage Held by Institutions

62.74% of the stock of Edap Tms is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EDAP Stock Analysis - Frequently Asked Questions

How have EDAP shares performed this year?

Edap Tms' stock was trading at $2.21 on January 1st, 2025. Since then, EDAP shares have decreased by 31.0% and is now trading at $1.5250.

How were Edap Tms' earnings last quarter?

Edap Tms S.A. (NASDAQ:EDAP) issued its quarterly earnings data on Thursday, May, 15th. The medical equipment provider reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.04. The medical equipment provider earned $16.37 million during the quarter, compared to analyst estimates of $16.56 million. Edap Tms had a negative net margin of 34.45% and a negative trailing twelve-month return on equity of 51.42%.
Read the conference call transcript.

How do I buy shares of Edap Tms?

Shares of EDAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Edap Tms own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Edap Tms investors own include Energous (WATT), Weatherford International (WFT), CTI BioPharma (CTIC), Petroleo Brasileiro S.A.- Petrobras (PBR), Advanced Micro Devices (AMD), Kandi Technologies Group (KNDI) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:EDAP
• CIK: 1041934
• Web: www.edap-tms.com
• Phone: (347) 215-3150
• Fax: 33-04-72-15-31-51
• Employees: 230
• Year Founded: 1979

Price Target and Rating

• Average Price Target for Edap Tms: $8.50
• High Price Target: $19.00
• Low Price Target: $2.00
• Potential Upside/Downside: +455.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.58 million
• Net Margins: -34.45%
• Pretax Margin: -33.90%
• Return on Equity: -51.42%
• Return on Assets: -26.43%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 1.74
• Quick Ratio: 1.21

Sales & Book Value

• Annual Sales: $62.77 million
• Price / Sales: 0.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.18 per share
• Price / Book: 1.30

Miscellaneous

• Outstanding Shares: 37,392,000
• Free Float: 37,306,000
• Market Cap: $57.21 million
• Optionable: Optionable
• Beta: N/A